Company: DVAX
Filing Date: 2025-05-07
Form Type: DEFA14A
Source: 0000930413-25-001648
Chunk: 1

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-07
Form: DEFA14A
Chunk 1
---
If you have any questions, your best resource is our proxy solicitor, MacKenzie
Partners (phone number information is noted above) who can help answer any questions you have.

From an operational perspective, it remains business as usual for all of
us and it is most important that we all remain focused on the critical work we are doing every day.

On behalf of our Board and management team, we want to thank everyone for
your focus and dedication. We sincerely appreciate your support.

Thank you,

Ryan

Forward-Looking Statements

This communication contains “forward-looking” statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to a number of risks and uncertainties. All statements that are not historical facts are forward-looking statements.
Forward-looking statements can generally be identified by the use of words such as “anticipate,” “believe,” “continue,”
“expect,” “will,” “may,” “plan,” “potential,” “seek,” “would”
and similar expressions, or the negatives thereof, or they may use future dates. Actual results may differ materially from those set
forth in this communication due to the risks and uncertainties inherent in our business, including, the risk that circumstances surrounding
or leading up to our 2025 Annual Meeting may change, risks relating to our ability to commercialize and supply HEPLISAV-B, and risks
related to the implementation of our long-term growth objectives, as well as other risks detailed in the “Risk Factors” section
of our Annual Report on Form 10-K for the financial year ended December 31, 2024 and any periodic filings made thereafter, as well as
discussions of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange
Commission. These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement
and we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information
becomes available. Information on Dynavax’s website at is not incorporated by reference in our current periodic
reports with the SEC.

Important Additional Information and Where to Find It

On April 17, 2025, the Company filed a definitive proxy statement on Schedule
14A (the “Proxy Statement”) and form of accompanying GOLD proxy card with the